MAIA Biotechnology, Inc. (MAIA)
ASE · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
MAIA Biotechnology Highlights THIO Phase 2 Progress in Annual Report
# 🧾 What This Document Is This is the **Annual Report to Shareholders (ARS)** for MAIA Biotechnology, Inc. Think of it as a company's "year-in-review" magazine, designed for investors. It’s different from the more technical 10-K filing—it’s shorter, more visual, and focuses on telling the company'
MAIA Biotechnology, Inc. — DEF 14A Filing
# 🧾 What This Document Is — A Roadmap for the Annual Vote This is a **Definitive Proxy Statement (DEF 14A)**. Think of it as the official rulebook and information packet for MAIA Biotechnology's upcoming annual shareholder meeting. The company is required to send this to shareholders so they can m
March 2026
MAIA Biotechnology, Inc. — 8-K Filing
# 🧾 What This Document Is This is a **press release** (filed as an Exhibit to an 8-K) from MAIA Biotechnology. The company is sharing exciting early results from a clinical trial of its cancer drug. They presented this data at a major medical conference in Copenhagen on March 27, 2026. 👉 **Why it
SEC filings
All filings →Insider trades
All insider trades →MAIA Biotechnology, Inc. has no reported insider trades in the last 90 days.